COMPARING THE CLINICAL AND RADIOGRAPHIC OUTCOMES OF PULPOTOMIES IN PRIMARY MOLARS USING BIOACTIVE ENDODONTIC MATERIALS AND FERRIC SULFATE - A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS

Gopinath VK 1 , Pulikkotil SJ 2 , Veettil SK 3 , Dharmarajan L 4 , Prakash PSG 4 , Dhar V 5 Show all authors , Jayaraman J 6

Affiliations 

  • 1 Department of Preventive and Restorative Dentistry, College of Dental Medicine, University of Sharjah, Sharjah, UAE. Electronic address: [email protected]
  • 2 Division of Clinical Dentistry, School of Dentistry, International Medical University, Kuala Lumpur, Malaysia
  • 3 Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, USA
  • 4 Department of Periodontics, S.R.M Dental College & Hospital, Ramapuram, Chennai, India
  • 5 Department of Orthodontics and Pediatric Dentistry, University of Maryland School of Dentistry, Baltimore, MD , USA
  • 6 Department of Pediatric Dentistry, Virginia Commonwealth University School of Dentistry, Richmond, VA, USA
J Evid Based Dent Pract, 2022 Dec;22(4):101770.
PMID: 36494111 DOI: 10.1016/j.jebdp.2022.101770

Abstract

OBJECTIVE: To compare the clinical and radiographic outcomes of pulpotomies in primary molars using bioactive endodontic materials and ferric sulfate.

DESIGN: The search was conducted in PubMed, Ebscohost, ProQuest, and Scopus databases till June 2021. Children undergoing pulpotomy therapy in primary molars treated with ferric sulfate (FS) and bioactive endodontic materials were evaluated for clinical and radiographic success. Meta-analysis was performed on a random-effects model to assess the success at 6,12,18, and 24 months. The quality of studies was evaluated using the Cochrane risk of bias tool for randomized trials RESULTS: No significant difference was observed between Mineral trioxide aggregate (MTA) and FS at 24 months for both clinical [RR0.98 (95%CI 0.15,6.34), I2 = 0%] and radiographic [RR0.74 (95%CI: 0.23,2.43), I2 = 0%] success. At 6 months [RR1.36 (95%CI: 0.10,19.34), I2 = 33%], no difference was observed in the clinical [RR1.00 (95%CI: 0.95,1.05), I2 = 0%] and radiographic success [RR0.99 (95%CI: 0.88,1.11), I2 = 51%] between Biodentine (BD), FS and radiographic success of calcium enriched cement and FS [RR0.25 (95%CI: 0.03, 2.22), I2 = 0%].

CONCLUSION: Amongst bioactive materials, MTA and FS demonstrated equal success rates in both clinical and radiographic outcomes with follow-up periods of up to 24 months. Future, high-quality trials are required to verify the result of the current review.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications